Drug Pricing in Canada and Beyond

This webinar will explore the latest developments in pharmaceutical pricing regulation, including the PMPRB Guidelines (which we anticipate by July 1st), alongside the executive order issued by President Trump, “Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients”. We will be joined by Wayne Critchley, a Senior Associate at Global Public Affairs, who advises biopharmaceutical and medical device companies. He has over twenty years of experience as a senior executive in the pharmaceutical sector within various government organizations. Also joining us is John Shakow from Washington’s King and Spalding, co-chair of the firm’s Life Sciences & Healthcare Industry Group, to offer a US perspective on the developments in pharmaceutical pricing under the Trump administration. Our expert panel will provide their reactions to these regulatory changes and their potential impact on the pharmaceutical industry in Canada.